EUCTR2007-005864-28-IT进行中（未招募）不适用
TREATMENT OF MINIMAL RESIDUAL DISEASE (MRD) IN ACUTE LEUKEMIA AFTER AN ALLOGENEIC STEM CELL TRANSPLANT - ND
FONDAZIONE RICERCA TRAPIANTO DI MIDOLLO OSSEO0 个研究点开始时间: 2009年3月23日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients with acute leukemia (AML and ALL), aged 18-70, Patients with a positive MRD post-transplant and they have no donor cells available at the time of MRD positivity. The stem cell source will be bone marrow or peripheral blood or cord blood according to availability .
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with a negative MRD post-transplant
研究者
相似试验
进行中（未招募）
不适用
Eradication of Minimal Residual Disease (MRD) in patients with Chronic Lymphocytic Leukaemia (CLL) with Alemtuzumab: A Phase II Study - UKCLL07Chronica Lymphocytic Leukaemia (CLL)EUCTR2006-000053-22-GBeeds Teaching Hospitals NHS Trust54
招募中
3 期
Randomized clinical study to evaluate utility of response adapted treatment in patients with newly diagnosed multiple myelomaCTRI/2021/11/037702Intramural grant of Tata Memorial Center Mumbai
已完成
2 期
Eradication of minimal residual disease (MRD) in chronic lymphocytic leukaemia (CLL) with alemtuzumab: a Phase II studyChronic lymphocytic leukaemia (CLL)CancerLeukaemiaISRCTN23153249eeds Teaching Hospitals NHS Trust (UK)47
进行中（未招募）
1 期
Treatment of MDS/AML patients with an impending hematological relapse with azacitidine alone or in combination with pevonedistatAcute myeloid leukemia (AML) and Myelodysplastic syndromes (MDS) with impending hematological relapseMedDRA version: 21.1Level: PTClassification code 10000880Term: Acute myeloid leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-004536-37-DEeipzig University14
已完成
Unknown
Survey on Minimal Residual Disease (MRD) Measurement in Multiple MyelomaMultiple MyelomaJPRN-UMIN000052475Sanofi K.K.158